Title: T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

Authors: Smaranda Gliga, Johannes Korth, Adalbert Krawczyk, Benjamin Wilde, Peter A. Horn, Oliver Witzke, Monika Lindemann, Melanie Fiedler

PII: S1386-6532(18)30157-4
DOI: https://doi.org/10.1016/j.jcv.2018.06.009
Reference: JCV 4018

To appear in: *Journal of Clinical Virology*

Received date: 11-2-2018
Revised date: 4-6-2018
Accepted date: 8-6-2018

Please cite this article as: Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, Lindemann M, Fiedler M, T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients, *Journal of Clinical Virology* (2018), https://doi.org/10.1016/j.jcv.2018.06.009

T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

Dr. Smaranda Gliga[1,3], Dr. Johannes Korth.[2], Adalbert Krawczyk, PhD[3], Prof. Dr. Benjamin Wilde[2], Prof. Dr. Peter Horn A.[1], Prof. Dr. Oliver Witzke[2,4], Prof. Dr. Monika Lindemann[1,*)], Dr. Melanie Fiedler[3,*)]

*) both authors contributed equally

[1] Institute for Transfusion Medicine, [2] Department of Nephrology, [3] Institute for Virology, [4] Department of Infectious Diseases, University Hospital Essen, University Duisburg Essen

Corresponding author:

Smaranda Stefania Gliga

Address: Bahnstr. 59, 40210 Dusseldorf, Germany

Email address: smaranda.gliga@gmail.com

Highlights:

- T-Track-CMV and QuantiFERON-CMV enable functional assessment of cell-mediated immunity
- T-Track-CMV better predictor of CMV reactivation in kidney transplant recipients
- High immediate early protein-1 responses indicate protection against reactivation